A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1400 participants.
Also called NCT06993792
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose screening
- Phase
- Phase 3
- Enrolled
- 1,400 participants
- Sponsor
- Registry
-
NCT06993792 -
2025-521098-14-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, China, Czechia, Germany, Japan, Puerto Rico
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06993792. Randomized; double masking; primary purpose screening. Start 2025-05-15 (actual); primary completion 2027-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06993792- Content hash
d43438f7c11bff939428362526bd3fdd2207a2048aab03c94836e32b579c8f8b